Overview

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Status:
RECRUITING

Trial end date:
2027-05-20

Target enrollment:

Participant gender:

Summary

This is a multi-center, single arm study to evaluate the efficacy and safety of donafenib in combination with envafolimab treatment in patients with high risk of recurrent hepatocellular carcinoma after radical surgery.

Phase:

PHASE2

Details

Lead Sponsor:

Anhui Provincial Hospital

Treatments:

donafenib
envafolimab